Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison
Authors:
- 1 September 2023
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 144, 105485
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?Frontiers in Pharmacology, 2020
- Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015–2018)Diabetes Care, 2020
- The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019Biologicals, 2020
- Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American surveyPharmacoepidemiology and Drug Safety, 2019
- Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in BrazilTherapeutic Advances in Musculoskeletal Disease, 2018
- Regulatory evaluation of biosimilars throughout their product life-cycleBulletin of the World Health Organization, 2018
- The road from development to approval: evaluating the body of evidence to confirm biosimilarityRheumatology, 2017
- Transparency in drug regulation: public assessment reports in Europe and AustraliaDrug Discovery Today, 2016
- Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin AmericaThe Journal of Dermatology, 2016
- The Regulation of Biosimilars in Latin AmericaCurrent Rheumatology Reports, 2016